Physician profile
Ryan D Lasota
NPI 1629396551
$1,146.50
in general payments reported to CMS, 2019-2025
22 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $56.02 · 2021: $213 · 2022: $273 · 2023: $224 · 2024: $81.57 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.57 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $180.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.15 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $129.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $71.31 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $57.08 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.19 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $55.66 | 2019-2022 | |
| Dexcom, INC. | $35.57 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Abbott Laboratories | $32.18 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.05 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $16.86 | 2021 | |
| Tris Pharma INC | $16.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.24 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $14.65 | 2025 | Omnipod |
| Eisai INC. | $14.34 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.48 | 2023 | Quviviq |
| Boston Scientific Corporation | $13.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.73 | 2021 | |
| Amgen INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lasota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.